Skip to main content

Table 1 Patients characteristics and univariate analysis of prognostic factors for survival

From: Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy

Characteristic LRFS OS
  n 5-year (%) 10-year (%) p 5-year (%) 10-year (%) p
 Age (y)        
 ≤ 35 134 76.0 70.4 0.020* 74.4 66.4 0.113
 > 35 934 85.4 82.7   80.5 67.4  
Menopausal status       
 Premenopausal 697 81.8 79.3 0.026* 80.3 68.9 0.589
 Postmenopausal 371 89.0 85.1   78.7 63.4  
Tumor size        
 T1-2 916 86.4 83.6 <0.001* 81.8 70.9 <0.001*
 T3-4 97 70.2 70.2   61.2 36.1  
 Unknown 55       
No of positive lymph nodes       
 pN1 (1–3) 780 88.7 86.1 <0.001* 86.1 77.7 <0.001*
 pN2 (4–9) 183 77.0 73.0   69.7 51.0  
 pN3 (≥ 10) 105 60.6 53.8   49.9 20.8  
Lymph node ratio       
 < 0.20 690 90.2 87.7 <0.001* 87.1 78.6 <0.001*
 0.21-0.65 269 78.6 74.9   75.1 60.9  
 > 0.65 109 57.5 52.3   44.3 21.5  
ER status        
 Positive 599 85.9 84.4 0.008* 83.9 69.0 <0.001*
 Negative 393 81.0 76.7   72.2 64.2  
 Unknown 76       
PR status        
 Positive 652 85.9 83.4 0.008* 83.0 72.6 <0.001*
 Negative 340 80.3 77.6   72.3 57.0  
 Unknown 76       
HER-2-neu status       
 Positive 321 81.8 79.7 0.077 75.6 66.2 0.026*
 Negative 585 85.5 82.0   82.7 71.2  
 Unknown 162       
Chemotherapy regimen        
 CMF 142 82.1 79.6 0.332 76.0 60.1 0.069
 Anthracycline and/or taxane 850 84.9 81.9   81.5 71.0  
 None/unknown 76       
Hormone therapy        
 Yes 718 85.7 82.5 0.032* 83.7 70.5 <0.001*
 None 350 81.4 78.8   71.2 60.4  
  1. LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor family 2; CMF, Cyclophosphamide, methotrexate, and 5-fluorouracil.
  2. *p<0.05 indicates a significant difference.